WG106

WG106 is a preclinical-stage stem cell therapy candidate being developed by Shenzhen Wingor Biotechnology. It is part of the company's pipeline of stem cell-based medicinal products (ranging from WG101 to WG108) designed to treat a variety of conditions, including immune-mediated, chronic, and degenerative diseases. The therapy utilizes the regenerative and immunomodulatory properties of stem cells to address unmet medical needs. While specific indications for WG106 have not been disclosed, it follows the development of more advanced candidates in the Wingor pipeline, such as WG101, which is currently in clinical trials for neurological or inflammatory conditions.